By Caroline Copley and Canice Leung
Oct 11 (Reuters) - Retired subway and bus driver Stanley De
Freitas had just celebrated his 70th birthday when he started
coughing, tiring easily and feeling short of breath. He was
diagnosed with pulmonary fibrosis, a severe scarring of the
lungs, and put on the wait list for a transplant.
"Life became unbearable. From the time I got up in the
morning until when I went to bed at night, I struggled through
every breath of air," De Freitas, now 74, told Reuters by phone
from his home in Toronto.
After two years, De Freitas was offered a lung, with one
significant downside: The donor had hepatitis C.
In October 2017, he became the first patient enrolled in a
just published study conducted at Toronto General Hospital
testing a technique that aimed to flush out and inactivate the
hepatitis C virus from donor lungs before a transplant.
The research comes amid a spike in available organs linked
to the opioid overdose crisis, meaning many are contaminated by
hepatitis C as the virus is commonly spread by sharing needles.
Since it can easily infect an organ recipient, those organs are
usually discarded despite the urgent need.
Data from the United Network for Organ Sharing (UNOS), which
matches donors with recipients, shows that 97 percent of people
waiting for a lung in the United States last year were unwilling
to accept an organ from a donor who tested positive for
hepatitis C.
While hepatitis C causes serious liver disease, the virus
can be present in the blood in other organs.
Researchers are testing different approaches to salvage
infected organs.
A study published in April showed that giving patients
antiviral therapy just hours after transplant surgery can
successfully attack the virus before it gains a foothold in the
recipient.
Eliminating the virus prior to transplant would simplify the
procedure for patients, said UNOS Chief Medical Officer David
Klassen. It could also significantly cut down on wasted donor
organs.
The technique used in Toronto, known as ex vivo lung
perfusion, keeps organs "alive" outside the body by pumping them
with a bloodless oxygenated liquid. They used ultraviolet C
light to irradiate the solution, aiming to deactivate the
hepatitis C virus and make it non-infectious.
Perfusion allows doctors to evaluate and potentially
rehabilitate organs for transplant, and buys them more time than
storage in ice boxes, which can cause tissue damage.
Toronto researchers used a solution from Sweden’s Xvivo
Perfusion AB XVIVO.ST with the hospital’s own ex vivo lung
perfusion system, a bubble-like machine made from off-the-shelf
components and an intensive care ventilator.
The study of 22 patients, published in The Lancet on
Wednesday, had mixed results. Adding light therapy significantly
decreased the amount of virus, but all but two of the patients
contracted hepatitis C, which is now curable.
Infected patients, including De Freitas, were treated with a
12-week course of antiviral drugs that rendered the virus
undetectable in all of them. Two of those patients relapsed but
were retreated and cured. One patient in the study died due to
complications from lung transplantation.
“All of the patients were in a very sick condition," said
Marcelo Cypel, surgical director at University Health Network in
Toronto and co-author of The Lancet study. "Perhaps some of them
wouldn't have made it to the transplant in time if they were not
offered these type of organs."
The researchers are planning another study combining
perfusion with a photodynamic therapy, a type of light they
believe could be more effective against the virus than
ultraviolet because it can penetrate the organ as well as the
solution.
OUT OF TRAGEDY, A GIFT
In the United States alone, almost 113,000 people are on
organ transplant lists, including more than 1,400 awaiting a new
lung. Hundreds die each year while on the list or after becoming
too sick to endure a transplant.
A tragic public health crisis has led to an unexpected
opportunity. With the jump in deaths from opioids such as heroin
and fentanyl, overdose victims now account for 13% of U.S. organ
donations, up from less than 4% a decade ago, according to UNOS.
Many of those organs are going to waste. For example, last
year less than 4% of hepatitis C positive donors in the United
States had lungs used for transplantation, the study's authors
said in the paper.
Other researchers are working with perfusion technology to
improve the function of donated lungs, hearts and livers.
Scientists at the University of Oxford were able to improve
the quality of 16 donated livers with signs of a fatty liver
disease. They treated donated organs outside the body with drugs
and captured fat that was washed out of the liver through a
filter on a transportable perfusion device developed by
Britain-based OrganOx, according to a study presented last year.
OrganOx has European Union clearance to use its device on
livers and hopes to gain U.S. approval by the end of 2020.
Perfusion device use currently is limited by cost, which can
stretch to hundreds of thousands of dollars, and by lack of
expertise and training.
De Freitas, though, is grateful the Toronto researchers are
testing perfusion to salvage organs.
“Every day I get up and I thank the Lord, I thank the
doctors because I am not supposed to be here," he said. "I am
supposed to be on the other side.”
<^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
Graphic: U.S. organ donors by mechanism of death https://tmsnrt.rs/2YQuYNK
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>
(Reporting by Caroline Copley in Berlin and Canice Leung in
Toronto; Editing by Elyse Tanouye and Bill Berkrot)
((Elyse.Tanouye@thomsonreuters.com;))